[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362506-105":59,"doc-detail-362506-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","direct-viral-mechanisms-underlying-the-onset-of-hbv-related-hepatocellular-carcinoma-and-implications-for-therapeutic-strategies","Direct Viral Mechanisms Underlying the Onset of HBV-Related Hepatocellular Carcinoma and Implications for Therapeutic Strategies","","Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality globally, and hepatitis B virus (HBV) infection is the dominant driver. HBV promotes HCC through continuous necro-inflammation as well as viral intrinsic oncogenic mechanisms, including HBV DNA integration, pro-oncogenic viral proteins such as HBx/HBs, and the build-up of tumorigenic mutations. Current NUC therapy controls replication but seldom achieves an HBV functional cure. Clinical evaluation targets direct antivirals and immune-therapeutics to improve outcomes and reduce HBV-related HCC burden.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/direct-viral-mechanisms-underlying-the-onset-of-hbv-related-hepatocellular-carcinoma-and-implications-for-therapeutic-strategies/362506/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/direct-viral-mechanisms-underlying-the-onset-of-hbv-related-hepatocellular-carcinoma-and-implications-for-therapeutic-strategies/362506.png","ImageObject",300,407,{"name":92,"@type":93},"WPS_1786070896","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",15,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"How does HBV contribute to the onset of HBV-related hepatocellular carcinoma (HCC)?","Question",{"text":113,"@type":114},"HBV drives HCC through indirect continuous necro-inflammation and through viral intrinsic factors including DNA integration, pro-oncogenic proteins (HBx/HBs), and accumulating mutations that enhance tumorigenicity.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Why do current nucleos(t)ide analog (NUC) therapies not eliminate HCC risk?",{"text":118,"@type":114},"NUCs substantially control HBV replication, but they rarely achieve an HBV functional cure, which is linked to HBsAg loss and better liver outcomes; therefore patients can remain at high HCC risk.",{"name":120,"@type":111,"acceptedAnswer":121},"What novel therapeutic strategies are described for HBV-related HCC prevention or treatment?",{"text":122,"@type":114},"The review highlights direct antivirals (e.g., nucleic acid polymers, siRNAs, antisense oligonucleotides, cccDNA inhibitors, capsid assembly modulators) and immune-therapeutics (therapeutic vaccines, checkpoint inhibitors, Toll-like receptor agonists) under clinical evaluation.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},362506,1790532868,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},549768072016,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Review  \nDirect Viral Mechanisms Underlying the Onset of HBV-Related Hepatocellular Carcinoma and Implications for Therapeutic Strategies  \nSimone La Frazia 1, Alessia Magnapera 1, Lorenzo Piermatteo 1, Stefano D’Anna 1, Leonardo Duca 2, Valentina Svicher 1,* and Romina Salpini 1, *  \n1 Department of Biology, University of Rome Tor Vergata, Via della Ricerca Scientifica, 1, 00133 Rome, Italy; [simone.la.frazia@uniroma2.it](simone.la.frazia@uniroma2.it) (S.L.F.); [alessiamagnapera97@gmail.com](alessiamagnapera97@gmail.com) (A.M.); [lorenzo.piermatteo@uniroma2.it](lorenzo.piermatteo@uniroma2.it) (L.P.); [stefanodanna26@gmail.com](stefanodanna26@gmail.com) (S.D.)  \n2 Laboratory of Electron Microscopy, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Viale Portuense 292, 00149 Rome, Italy; [duca.leonardo@hotmail.it](duca.leonardo@hotmail.it)  \n* [Correspondence: valentina.svicher@uniroma2.it](Correspondence: valentina.svicher@uniroma2.it) (V.S.); [rsalpini@gmail.com](rsalpini@gmail.com) (R.S.); Tel.: +39-06-72594804 (V.S. & R.S.)  \nAbstract  \nHepatocellular carcinoma (HCC) represents the second leading cause of cancer mortality worldwide and is mostly caused by hepatitis B virus (HBV) infection. HBV can induce HCC by an indirect mechanism of continuous necro-inflammation, contributing to hepatocyte damage and promoting cancer, as well as by viral intrinsic factors. Among them, the major contributors to the development of HBV-related HCC are represented by (i) HBV DNA integration in genes modulating cell proliferation,(ii) HBV pro-oncogenic proteins, such as HBx and HBs, and (iii) the accumulation of viral mutations, enhancing the tumorigenic features of HBV proteins. The currently available antiviral treatments, based on the usage of Nucleos(t)ide analogs (NUCs), substantially control HBV replication. However, even a successful NUC treatment does not completely abrogate HCC risk, since it rarely allows achievement of an HBV functional cure, the therapeutic end-point associated with HBsAg loss and more favorable liver outcomes. To date, novel therapeutic strategies based on innovative direct antivirals (nucleic acid polymers, small interfering RNAs, antisense oligonucleotides, covalently closed circular DNA (cccDNA) inhibitors, and capsid assembly modulators) and immune-therapeutics (therapeutic vaccines, checkpoint inhibitors, and Toll-like receptor agonists) are under evaluation in clinical trials. These approaches are showing promising data in terms of an HBV functional cure, thus representing novel strategies that could be beneficial for reducing the burden of HBV-related HCC. Lastly, further efforts in drug development are necessary to identify new compounds that could achieve a sterilizing HBV cure, implying the complete elimination of cccDNA and integrated HBV DNA, the only end-point that completely eradicates HBV and its related oncogenic risk.  \nAcademic Editor: Fan Zhu  \nReceived: 16 December 2025  \nRevised: 23 January 2026  \nAccepted: 28 January 2026  \nPublished: 29 January 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \nKeywords: hepatocellular carcinoma; hepatitis B virus; HBV oncoproteins; HBV DNA integration; Nucleos(t)ide analogs; novel anti-HBV drugs; HBV functional cure; HBV sterilizing cure  \n1. Introduction  \nHepatocellular carcinoma (HCC) is the sixth most common cancer and the third cause of cancer mortality worldwide [1], with more than one million deaths predicted in 2040 [2] .  \nViral hepatitis together with alcohol-associated liver disease and non-alcoholic fatty liver disease (NAFLD) represent the major risk factors for the development of HCC [3–5] . Among viral agents, chronic infection with hepatitis B virus (HBV) represents the leading cause of HCC worldwide. In particular, it has been estimated that in 2022, one-third ","cbCaiuZBvJkkTZui","https://ap.wps.com/l/cbCaiuZBvJkkTZui","pdf",1078388,27,"English","# Abstract\n# Introduction","[{\"question\":\"How does HBV contribute to the onset of HBV-related hepatocellular carcinoma (HCC)?\",\"answer\":\"HBV drives HCC through indirect continuous necro-inflammation and through viral intrinsic factors including DNA integration, pro-oncogenic proteins (HBx/HBs), and accumulating mutations that enhance tumorigenicity.\"},{\"question\":\"Why do current nucleos(t)ide analog (NUC) therapies not eliminate HCC risk?\",\"answer\":\"NUCs substantially control HBV replication, but they rarely achieve an HBV functional cure, which is linked to HBsAg loss and better liver outcomes; therefore patients can remain at high HCC risk.\"},{\"question\":\"What novel therapeutic strategies are described for HBV-related HCC prevention or treatment?\",\"answer\":\"The review highlights direct antivirals (e.g., nucleic acid polymers, siRNAs, antisense oligonucleotides, cccDNA inhibitors, capsid assembly modulators) and immune-therapeutics (therapeutic vaccines, checkpoint inhibitors, Toll-like receptor agonists) under clinical evaluation.\"}]","Direct Viral Mechanisms Underlying the Onset of HBV-Related Hepatocellular Carcinoma and Implications for Therapeutic Strategies | PDF",1790148012,68,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6be0e61a507e0c25eabd7f61550d83db.webp",983,1390,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b901ab2d87fdf8d563e7e8d369cb2501.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bd0e56ca1bbbb8a63f689d79dd8b32c9.webp",981,1387,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8ff709049f1e7fa827b9ba2c8f89d53a.webp",980,1385]